Inogen (INGN) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
6 Nov, 2026Strategic positioning
Transitioning from a single-product oxygen business to a respiratory care platform spanning oxygen, airway clearance, sleep therapy, and digital solutions.
Strategic priorities: drive top-line growth, advance profitability, and expand the innovation pipeline.
Portfolio expansion targets COPD, bronchiectasis, and sleep apnea, with an estimated ~70 million U.S. patients across these conditions.
Existing advantages include POC technology, brand recognition, physician confidence, and established distributor relationships.
Markets and product expansion
Estimated U.S. addressable markets: $0.4B for POCs, $0.3B for stationary oxygen concentrators, $2.2B for CPAP masks and accessories, and $0.5B for airway clearance.
Voxi 5 launched in Q2 2025, adding an estimated $300M to the oxygen addressable market; it serves stationary oxygen users, who represent 90% of LTOT patients.
Aurora CPAP masks launched in Q1 2026 into a U.S. market estimated at $2.2B, with high-single-digit growth and 20–30% patient overlap with COPD.
Simeox 200 received FDA clearance in Q4 2024; airway clearance targets an estimated $500M U.S. bronchiectasis market as reimbursement advances.
POC share of ambulatory oxygen new patient starts rose from 38% in 2019 to 41% in 2025; tanks retained 59% share in 2025, with ~350,000 patients starting on tanks annually.
Financial performance
FY25 revenue was $349M, gross margin 44.2%, adjusted EBITDA $2.7M, and adjusted net loss $8.0M; cash, equivalents, marketable securities and restricted cash totaled $121M, with no debt, as of Dec. 31, 2025.
Revenue increased from $316M in FY23 to $336M in FY24 and $349M in FY25; 7 of the last 8 quarters delivered mid-single-digit revenue growth.
Operating loss improved from $109M in FY23 to $43M in FY24 and $30M in FY25; net loss improved from $102M to $36M and $23M over the same years.
Adjusted EBITDA improved from a loss of $37.8M in FY23 to a loss of $9.5M in FY24 and income of $2.7M in FY25, the first positive result since 2021.
FY25 revenue mix: U.S. sales 45%, international sales 40%, and U.S. rentals 15%.
Latest events from Inogen
- U.S. growth and rental sale anchor a reset after Q3 losses and weaker international demand.INGN
Q3 2026 - Q2 2026 revenue up 3% to $95.1M, with strong international growth and improved EBITDA.INGN
Q2 2026 - Achieved a financial turnaround and expanded into new respiratory care markets with innovative products.INGN
Corporate presentation - Diversified platform, new products, and financial turnaround position for sustained growth.INGN
Corporate presentation - Directors, auditors, and compensation approved; board declassification amendment failed.INGN
AGM 2026 - Revenue up 3.4% to $85.1M, driven by international growth despite higher net loss.INGN
Q1 2026 - Proxy details director elections, governance reforms, and expanded equity incentives for 2026.INGN
Proxy filing - Shareholders will vote on board declassification, equity plan expansion, and key governance changes.INGN
Proxy filing - New products and leadership drive growth, margin expansion, and strategic transformation.INGN
25th Annual Needham Virtual Healthcare Conference